Lilly’s Hotly Anticipated Oral Weight Loss Drug Delivers Lukewarm Results in Phase III
Eli Lilly’s orforglipron cut body weight as expected in the Phase III ATTAIN-1 trial, but to a lesser extent than rival Novo Nordisk’s semaglutide, falling into analysts’ bear scenario for the oral med.
Lilly’s Hotly Anticipated Oral Weight Loss Drug Delivers Lukewarm Results in Phase III Read More »
